Boiron Past Earnings Performance
Past criteria checks 1/6
Boiron has been growing earnings at an average annual rate of 1.8%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been declining at an average rate of 2.5% per year. Boiron's return on equity is 6%, and it has net margins of 4.9%.
Key information
1.8%
Earnings growth rate
2.0%
EPS growth rate
Pharmaceuticals Industry Growth | 16.3% |
Revenue growth rate | -2.5% |
Return on equity | 6.0% |
Net Margin | 4.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Market Participants Recognise Boiron SA's (EPA:BOI) Earnings
Nov 23Calculating The Intrinsic Value Of Boiron SA (EPA:BOI)
Jan 26Boiron (EPA:BOI) Has Re-Affirmed Its Dividend Of €0.95
Apr 28Estimating The Intrinsic Value Of Boiron SA (EPA:BOI)
Jan 22Is Boiron SA's (EPA:BOI) 2.3% Dividend Worth Your Time?
Apr 30Boiron (EPA:BOI) Has A Pretty Healthy Balance Sheet
Apr 12Reflecting on Boiron's (EPA:BOI) Share Price Returns Over The Last Three Years
Mar 08A Look At The Intrinsic Value Of Boiron SA (EPA:BOI)
Feb 18Does The Market Have A Low Tolerance For Boiron SA's (EPA:BOI) Mixed Fundamentals?
Feb 02Should You Buy Boiron SA (EPA:BOI) For Its Dividend?
Jan 19Does Boiron's (EPA:BOI) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 27What Kind Of Shareholders Hold The Majority In Boiron SA's (EPA:BOI) Shares?
Dec 14Revenue & Expenses Breakdown
How Boiron makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 482 | 24 | 307 | 6 |
31 Mar 24 | 487 | 30 | 307 | 6 |
31 Dec 23 | 493 | 36 | 307 | 6 |
30 Sep 23 | 505 | 42 | 312 | 6 |
30 Jun 23 | 517 | 48 | 317 | 6 |
31 Mar 23 | 526 | 46 | 314 | 6 |
31 Dec 22 | 534 | 45 | 310 | 6 |
30 Sep 22 | 528 | 48 | 298 | 5 |
30 Jun 22 | 522 | 51 | 286 | 4 |
31 Mar 22 | 489 | 40 | 281 | 4 |
31 Dec 21 | 455 | 29 | 277 | 3 |
30 Sep 21 | 453 | 23 | 286 | 3 |
30 Jun 21 | 450 | 18 | 296 | 3 |
31 Mar 21 | 482 | 22 | 304 | 3 |
31 Dec 20 | 514 | 26 | 312 | 4 |
30 Sep 20 | 534 | 33 | 318 | 3 |
30 Jun 20 | 554 | 40 | 324 | 3 |
31 Mar 20 | 556 | 40 | 334 | 3 |
31 Dec 19 | 557 | 41 | 344 | 3 |
30 Sep 19 | 569 | 38 | 351 | 3 |
30 Jun 19 | 580 | 35 | 358 | 4 |
31 Mar 19 | 592 | 46 | 360 | 4 |
31 Dec 18 | 604 | 57 | 363 | 4 |
30 Sep 18 | 609 | 66 | 360 | 4 |
30 Jun 18 | 613 | 75 | 357 | 4 |
31 Mar 18 | 615 | 77 | 359 | 4 |
31 Dec 17 | 618 | 78 | 360 | 4 |
30 Sep 17 | 616 | 77 | 361 | 4 |
30 Jun 17 | 615 | 76 | 362 | 4 |
31 Mar 17 | 615 | 77 | 359 | 4 |
31 Dec 16 | 614 | 78 | 356 | 4 |
30 Sep 16 | 616 | 78 | 357 | 4 |
30 Jun 16 | 617 | 79 | 358 | 4 |
31 Mar 16 | 612 | 76 | 356 | 4 |
31 Dec 15 | 608 | 74 | 354 | 4 |
30 Sep 15 | 616 | 83 | 352 | 4 |
30 Jun 15 | 624 | 91 | 349 | 4 |
31 Mar 15 | 617 | 90 | 348 | 5 |
31 Dec 14 | 610 | 89 | 346 | 5 |
30 Sep 14 | 607 | 83 | 346 | 6 |
30 Jun 14 | 604 | 76 | 345 | 6 |
31 Mar 14 | 611 | 79 | 345 | 6 |
31 Dec 13 | 618 | 82 | 345 | 6 |
Quality Earnings: BOI has a large one-off loss of €8.0M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: BOI's current net profit margins (4.9%) are lower than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BOI's earnings have grown by 1.8% per year over the past 5 years.
Accelerating Growth: BOI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BOI had negative earnings growth (-50.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-19.9%).
Return on Equity
High ROE: BOI's Return on Equity (6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 08:38 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Boiron SA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Stéphan Dubosq | Arkeon Finance |
Guillaume Cuvillier | Gilbert Dupont |
Stephanie Lefebvre | Gilbert Dupont |